Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2019-03-28 Governance Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC Appendix 4G 10 pages 226.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures related to the Corporate Governance Council Principles and Recommendations for the financial year ended 31 December 2018. The document is a corporate governance statement that is part of or accompanies the annual report, providing detailed governance practices and compliance with ASX recommendations. It is not the full annual report itself but a governance disclosure document required to be lodged with the ASX alongside the annual report. Given the content and regulatory references, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2019-03-28 English
Preliminary Final Report 69 pages 919.3KB
Annual Report Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E Preliminary Final Report For the year ended 31 December 2018' and contains detailed financial data including revenue, EBITDA, net loss, dividends, and operational strategy for the full fiscal year ending December 31, 2018. It includes comprehensive financial statements references (performance, position, cash flows, retained earnings), management commentary, and notes on audit status. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are equivalent to annual reports or 10-K filings in other jurisdictions. The content includes detailed financial performance and management discussion, consistent with an Annual Report (10-K) filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2018
2019-02-26 English
Dividend/Distribution - CYC 3 pages 26.6KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It is a formal announcement of dividend payment details rather than a full financial report or analysis. The document length is under 5,000 characters and it primarily serves to inform shareholders about dividend specifics. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2019-02-26 English
CYC Update - R&D Tax Incentive, USFDA, German Litigation 2 pages 141.5KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement providing updates on several operational and financial matters: receipt of R&D tax incentive funds, enrollment milestones in a clinical trial, and receipt of litigation proceeds. It is addressed to the Australian Securities Exchange and is titled 'COMPANY UPDATE'. The content is not a full financial report, audit, or earnings release, but rather a brief update on specific corporate developments and financial receipts. The document length is 4625 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no indication that this is a full Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification letter. The nature of the content fits best with a Capital/Financing Update (CAP) as it discusses receipt of funds from R&D tax incentives and litigation, which are financial inflows relevant to capital or financing activities. Therefore, the most appropriate classification is CAP with high confidence.
2019-01-23 English
CANM Endorses Technegas 3 pages 242.7KB
Capital/Financing Update Classification · 90% confidence The document is a detailed business and trading update from Cyclopharm Limited dated 19 December 2018. It discusses new Canadian guidelines endorsing their product Technegas, progress in the US FDA clinical trial program, and expectations for FY18 revenue. It also mentions ongoing litigation and financial outlook but does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report or Annual Report. The document is longer than 5,000 characters and provides substantive operational and financial updates rather than just announcing a report or certifying it. It is not a full earnings release since it provides more detailed business updates and outlook. Therefore, the best fit is a Capital/Financing Update (CAP) as it includes updates on clinical trials, regulatory approval progress, and financial expectations relevant to capital and financing activities.
2018-12-18 English
CYC - FNN Interview 1 page 420.4KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 29 October 2018 from Cyclopharm Limited, providing shareholders with a video interview link regarding the company's meeting with the USFDA for approval of Technegas. It includes contact information and a description of the company's product and mission. There are no financial statements, no detailed financial data, no regulatory filings, no voting results, no management changes, no audit information, and no report attachments. The document is primarily an informational announcement about an interview and company product, not a formal report or regulatory filing. Given the short length (2360 characters) and the nature of the content, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2018-10-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.